Circulating levels of angiogenesis-related growth factors in breast cancer: A study to profile proteins responsible for tubule formation

Barron, Gemma A.; Goua, Marie; Wahle, Klaus W.J.; Bermano, Giovanna

doi:10.3892/or.2017.5803

Cited by 29 publications

(24 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Through the release of soluble mediators like cytokines tumor cells are able to communicate with adjacent cell types like tumor-associated macrophages (TAMs), cancer-associates fibroblasts (CAFs), and ECs. Some factors have pro-angiogenic effects which include vascular endothelial growth factor (VEGF), fibroblast growth factors (FGFs), hepatocyte growth factor (HGF), platelet derived growth factor (PDGF), monocyte chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1β, interleukin (IL)-8, and CC-chemokine ligand 5 (CCL5) [ 17 ]. Chemosensory reception of these factors manipulates the cells into a pro-tumoral state supporting carcinogenesis [ 14 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

Development of Radiotracers for Breast Cancer—The Tumor Microenvironment as an Emerging Target

Heesch

Maurer

Stickeler

et al. 2020

Cells

View full text Add to dashboard Cite

Molecular imaging plays an increasingly important role in the diagnosis and treatment of different malignancies. Radiolabeled probes enable the visualization of the primary tumor as well as the metastases and have been also employed in targeted therapy and theranostic approaches. With breast cancer being the most common malignancy in women worldwide it is of special interest to develop novel targeted treatments. However, tumor microenvironment and escape mechanisms often limit their therapeutic potential. Addressing tumor stroma associated targets provides a promising option to inhibit tumor growth and angiogenesis and to disrupt tumor tissue architecture. This review describes recent developments on radiolabeled probes used in diagnosis and treatment of breast cancer especially in triple negative type with the focus on potential targets offered by the tumor microenvironment, like tumor associated macrophages, cancer associated fibroblasts, and endothelial cells.

show abstract

Section: Introductionmentioning

confidence: 99%

Development of Radiotracers for Breast Cancer—The Tumor Microenvironment as an Emerging Target

Heesch

Maurer

Stickeler

et al. 2020

Cells

View full text Add to dashboard Cite

show abstract

“…Indeed, mice treated with IFN-␣ showed a weaker response to oncolytic alphavirus M1 treatment (46). These results may be extrapolated to FGFs, as the expression of various FGFs is upregulated in ovarian cancer, breast cancer, prostate cancer, and colon cancer (47)(48)(49)(50)(51). In tumor microenvironments with high FGF levels, replication of oncolytic VSV or coxsackievirus is possibly naturally inhibited.…”

Section: Discussionmentioning

confidence: 98%

Secretome Screening Reveals Fibroblast Growth Factors as Novel Inhibitors of Viral Replication

Asten

Raaben

Nota

et al. 2018

J Virol

View full text Add to dashboard Cite

Cellular antiviral programs can efficiently inhibit viral infection. These programs are often initiated through signaling cascades induced by secreted proteins such as type I interferons, IL-6 or TNF-α. Here, we generated an arrayed library of 756 human secreted proteins to perform a secretome screen focused on the discovery of novel modulators of viral entry and/or replication. The individual secreted proteins were tested for their capacity to inhibit infection by two replication-competent recombinant vesicular stomatitis viruses (VSV) with distinct glycoproteins utilizing different entry pathways. Fibroblast growth factor 16 (FGF16) was identified and confirmed as the most prominent novel inhibitor of both VSVs and therefore of viral replication and not entry. Importantly, an antiviral interferon signature was completely absent in FGF16 treated cells. Nevertheless, the antiviral effect of FGF16 is broad as it was evident on multiple cell types and also on infection of Coxsackievirus. In addition, other members of the FGF family also inhibited viral infection. Thus, our unbiased secretome screen revealed a novel protein family capable of inducing a cellular antiviral state. This previously unappreciated role of the FGF family may have implications for the development of new antivirals and the efficacy of oncolytic virus therapy.Viruses infect human cells in order to replicate, while human cells aim to resist infection. Several cellular antiviral programs have therefore evolved to resist infection. Knowledge of these programs is essential for the design of antiviral therapeutics in the future. The induction of antiviral programs is often initiated by secreted proteins such as interferons. We hypothesized that other secreted proteins may also promote resistance to viral infection. Thus we tested 756 human secreted proteins for their capacity to inhibit two pseudotypes of vesicular stomatitis virus (VSV). In this first secretome screen on viral infection we identified fibroblast growth factor 16 (FGF16) as a novel antiviral against multiple VSV pseudotypes as well as Coxsackievirus. Subsequent testing of other FGF family members revealed that FGF signaling generally inhibits viral infection. This finding may lead to the development of new antivirals and may also be applicable to enhance oncolytic virus therapy.

show abstract

“…Enoxaparin in different forms has an inhibitory effect on various cancers [10][11][12][13][14][15]. Enoxaparin and other derivatives of heparin suppress various cancers [16][17][18]. However, enoxaparin is reported to have little effect on tumor size in breast cancer in women [26].…”

Section: Discussionmentioning

confidence: 99%

“…It affects a variety of cancers, such as breast cancer in woman [13,14]. Angiogenesis supplies oxygen and nutrients to breast cancer tissues to promote tumor development and metastasis [15,16]. It is a physiological process where epithelial cells proliferate to promote neovascularization.…”

Section: Introductionmentioning

confidence: 99%

Effects of Enoxaparin Emulsion on Dimethylbenzanthracene-induced Breast Cancer in Female Rats

Bolandpayeh

Hassanpour-Ezzati

Mousavi

2018

RMM

View full text Add to dashboard Cite

Introduction: Enoxaparin is an anticoagulant medication. Anticoagulation inhibits tumor cell-mediated release of angiogenic proteins and diminishes angiogenic response. Angiogenesis is an important event in various cancers such as breast cancer. Angiogenesis provide oxygen and nutrients to tumor cells and causes tumor progression. The aim of the present study was to evaluate the anti-angiogenesis effect of an enoxaparin cream on breast cancer induced by dimethylbenzanthracene in rats. Methods: In this experimental in vivo study, 50 Wistar female rats were divided into negative control (vehicle), positive control (cream base), and 3 groups with enoxaparin treatment (40, 60, and 80 mg/ml). After one month of treatment along with breast cancer induction by dimethylbenzanthracene, breast tissue samples were isolated and stained with hematoxylin-eosin, and tumor growth suppression rate was calculated. Tumor size (length and width) was measured using a clipper, and the tumor volume was calculated using the following formula: V = (L × W × W)/2, where V is tumor volume, W is tumor width, L is tumor length. The data were analyzed using one-way ANOVA and Tukey’s post hoc test. Results: Tumor suppression was significantly increased in enoxaparin treatment groups compared to the positive control group (40 mg/ml of enoxaparin treated versus positive control group; P = 0.017, 60 mg/ml of enoxaparin treated versus positive control; P = 0.015, 40 mg/ml of enoxaparin treated versus positive control; P = 0.009, 60 mg/ml of enoxaparin treated versus 40 mg/ml of enoxaparin treated; P = 0.019, and 80 mg/ml of enoxaparin treated versus 40 mg/ml of enoxaparin treated; P = 0.011 in a dose-dependent manner. Conclusion: Enoxaparin inhibits breast cancer in a dose-dependent manner. The application of enoxaparin cream in patients with breast cancer may considerably reduce tumor growth.

show abstract

Circulating levels of angiogenesis-related growth factors in breast cancer: A study to profile proteins responsible for tubule formation

Cited by 29 publications

References 24 publications

Development of Radiotracers for Breast Cancer—The Tumor Microenvironment as an Emerging Target

Development of Radiotracers for Breast Cancer—The Tumor Microenvironment as an Emerging Target

Secretome Screening Reveals Fibroblast Growth Factors as Novel Inhibitors of Viral Replication

Effects of Enoxaparin Emulsion on Dimethylbenzanthracene-induced Breast Cancer in Female Rats

Contact Info

Product

Resources

About